326 related articles for article (PubMed ID: 28150740)
1. TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors.
Matsuse M; Yabuta T; Saenko V; Hirokawa M; Nishihara E; Suzuki K; Yamashita S; Miyauchi A; Mitsutake N
Sci Rep; 2017 Feb; 7():41752. PubMed ID: 28150740
[TBL] [Abstract][Full Text] [Related]
2. Effects of Coexistent BRAF
Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ
Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854
[TBL] [Abstract][Full Text] [Related]
3. TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer.
Myung JK; Kwak BK; Lim JA; Lee MC; Kim MJ
Cancer Res Treat; 2016 Jul; 48(3):942-7. PubMed ID: 26727717
[TBL] [Abstract][Full Text] [Related]
4. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
[TBL] [Abstract][Full Text] [Related]
6. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF
Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T
Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
[TBL] [Abstract][Full Text] [Related]
7. Frequent BRAF
Oishi N; Kondo T; Nakazawa T; Mochizuki K; Inoue T; Kasai K; Tahara I; Yabuta T; Hirokawa M; Miyauchi A; Katoh R
Endocr Pathol; 2017 Jun; 28(2):103-111. PubMed ID: 28176151
[TBL] [Abstract][Full Text] [Related]
8.
Tanaka A; Matsuse M; Saenko V; Nakao T; Yamanouchi K; Sakimura C; Yano H; Nishihara E; Hirokawa M; Suzuki K; Miyauchi A; Eguchi S; Yoshiura KI; Yamashita S; Nagayasu T; Mitsutake N
Thyroid; 2019 Aug; 29(8):1105-1114. PubMed ID: 31286848
[No Abstract] [Full Text] [Related]
9. Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC.
George JR; Henderson YC; Williams MD; Roberts DB; Hei H; Lai SY; Clayman GL
J Clin Endocrinol Metab; 2015 Dec; 100(12):E1550-9. PubMed ID: 26461266
[TBL] [Abstract][Full Text] [Related]
10. A six-genotype genetic prognostic model for papillary thyroid cancer.
Shen X; Liu R; Xing M
Endocr Relat Cancer; 2017 Jan; 24(1):41-52. PubMed ID: 27875244
[TBL] [Abstract][Full Text] [Related]
11. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
Huang M; Yan C; Xiao J; Wang T; Ling R
Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
[TBL] [Abstract][Full Text] [Related]
12. TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas.
Bullock M; Ren Y; O'Neill C; Gill A; Aniss A; Sywak M; Sidhu S; Delbridge L; Learoyd D; de Vathaire F; Robinson BG; Clifton-Bligh RJ
Clin Endocrinol (Oxf); 2016 Aug; 85(2):283-90. PubMed ID: 26667986
[TBL] [Abstract][Full Text] [Related]
13. Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid Cancer.
Trybek T; Walczyk A; Gąsior-Perczak D; Pałyga I; Mikina E; Kowalik A; Hińcza K; Kopczyński J; Chrapek M; Góźdź S; Kowalska A
Endocrinology; 2019 Oct; 160(10):2328-2338. PubMed ID: 31305897
[TBL] [Abstract][Full Text] [Related]
14. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O
Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032
[TBL] [Abstract][Full Text] [Related]
15. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
[TBL] [Abstract][Full Text] [Related]
16. [
Yang T; Chen C; Pan NF; Sun LY; Jiang XL; Li JN; Tang Y; Jiang Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 50(6):919-924. PubMed ID: 31880125
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas.
Nakayama H; Yoshida A; Nakamura Y; Hayashi H; Miyagi Y; Wada N; Rino Y; Masuda M; Imada T
Anticancer Res; 2007; 27(5B):3645-9. PubMed ID: 17972530
[TBL] [Abstract][Full Text] [Related]
19. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
[TBL] [Abstract][Full Text] [Related]
20. Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis.
Vuong HG; Altibi AM; Duong UN; Ngo HT; Pham TQ; Tran HM; Oishi N; Mochizuki K; Nakazawa T; Hassell L; Katoh R; Kondo T
Tumour Biol; 2017 Oct; 39(10):1010428317713913. PubMed ID: 29037127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]